Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG)
Regional hypertension guidelines now formally recommend proven cardio-protective drugs like SGLT2 inhibitors for diabetes patients, offering clearer treatment pathways across Asia-Pacific.
A 15-country Asia-Pacific expert panel used a modified Delphi approach and GRADE framework to issue joint hypertension-in-diabetes management guidelines, formally endorsing SGLT2 inhibitors, GLP-1 receptor agonists, and ARNIs for cardio-renal protection. The consensus targets BP <130/80 mmHg for most patients and advocates single-pill combinations for adherence, providing a region-specific framework for an area experiencing a surge in cardiometabolic disease.
What the study was
- Study design
- Systematic review + modified Delphi consensus (15-country multidisciplinary panel)
- Population
- Adults with hypertension and type 2 diabetes in Asia-Pacific region
- Category
- Prevention
- Maturity
- Potentially Practice-Changing
- Journal
- Journal of Human Hypertension
Why it surfaced
Major regional guideline (15 countries, GRADE-graded) explicitly endorsing SGLT2i and GLP-1 RA for cardio-renal protection in diabetes hypertension; directly actionable across Asia-Pacific; endorsed by both hypertension and diabetes societies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.